Healthcare provider profile · identity verified

Roberto Encarnacion, MD

General Practice · BARRANQUITAS, PR · NPI 1154480473

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Synthroid	Levothyroxine Sodium	486	131
Pantoprazole Sodium	Pantoprazole Sodium	351	57
Rosuvastatin Calcium	Rosuvastatin Calcium	299	117
Losartan Potassium	Losartan Potassium	270	95
Amlodipine Besylate	Amlodipine Besylate	261	90
Omeprazole	Omeprazole	258	66
Famotidine	Famotidine	220	61
Clonazepam	Clonazepam	214	42
Atorvastatin Calcium	Atorvastatin Calcium	196	65
Gabapentin	Gabapentin	193	77
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	193	132
Albuterol Sulfate Hfa	Albuterol Sulfate	192	96
Tramadol Hcl	Tramadol Hcl	190	38
Metformin Hcl	Metformin Hcl	169	55
Prednisone	Prednisone	134	95
Lisinopril	Lisinopril	130	42
Diclofenac Potassium	Diclofenac Potassium	126	57
Metoprolol Tartrate	Metoprolol Tartrate	119	40
Montelukast Sodium	Montelukast Sodium	119	54
Metoprolol Succinate	Metoprolol Succinate	115	43
Meloxicam	Meloxicam	114	66
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	109	50
Baclofen	Baclofen	106	42
Tizanidine Hcl	Tizanidine Hcl	101	64
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	98	38
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	94	11
Hydrochlorothiazide	Hydrochlorothiazide	90	37
Simvastatin	Simvastatin	83	29
Tamsulosin Hcl	Tamsulosin Hcl	80	31
Temazepam	Temazepam	80	14
Alendronate Sodium	Alendronate Sodium	78	29
Diclofenac Sodium	Diclofenac Sodium	70	40
Dicyclomine Hcl	Dicyclomine Hcl	66	39
Farxiga	Dapagliflozin Propanediol	64	17
Amitriptyline Hcl	Amitriptyline Hcl	59	27
Azithromycin	Azithromycin	59	49
Glimepiride	Glimepiride	58	20
Lantus	Insulin Glargine,hum.Rec.Anlog	58	15
Meclizine Hcl	Meclizine Hcl	56	22
Nabumetone	Nabumetone	54	12
Ciprofloxacin Hcl	Ciprofloxacin Hcl	51	43
Clopidogrel	Clopidogrel Bisulfate	51	19
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	49	19
Fluticasone Propionate	Fluticasone Propionate	47	15
Glipizide	Glipizide	47	16
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	47	43
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	46	18
Pioglitazone Hcl	Pioglitazone Hcl	46	18
Irbesartan	Irbesartan	45	13
Sucralfate	Sucralfate	45	17
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	43	11
Pentoxifylline	Pentoxifylline	42	11
Sertraline Hcl	Sertraline Hcl	42	11
Ibandronate Sodium	Ibandronate Sodium	41	14
Colchicine	Colchicine	40	suppressed
Nifedipine Er	Nifedipine	37	11
Trazodone Hcl	Trazodone Hcl	34	11
Betamethasone Dipropionate	Betamethasone Dipropionate	33	24
Humulin N	Insulin Nph Human Isophane	33	suppressed
Jardiance	Empagliflozin	33	suppressed
Dexamethasone	Dexamethasone	31	30
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	31	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	30	28
Latanoprost	Latanoprost	30	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	29	suppressed
Allopurinol	Allopurinol	28	suppressed
Ketorolac Tromethamine	Ketorolac Tromethamine	28	22
Lansoprazole	Lansoprazole	26	suppressed
Albuterol Sulfate	Albuterol Sulfate	25	22
Neomycin-Polymyxin-Dexameth	Neomycin/Polymyxin B/Dexametha	24	19
Sulindac	Sulindac	24	20
Candesartan Cilexetil	Candesartan Cilexetil	23	suppressed
Lorazepam	Lorazepam	23	suppressed
Naproxen	Naproxen	23	suppressed
Furosemide	Furosemide	22	11
Ketoconazole	Ketoconazole	22	16
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	22	suppressed
Eliquis	Apixaban	21	suppressed
Rivastigmine	Rivastigmine	21	suppressed
Timolol Maleate	Timolol Maleate	21	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	20	suppressed
Humalog Mix 75-25	Insulin Lispro Protamin/Lispro	20	suppressed
Clobetasol Propionate	Clobetasol Propionate	19	suppressed
Neomycin-Polymyxin-Hydrocort	Neomycin/Polymyxin B/Hydrocort	19	16
Silver Sulfadiazine	Silver Sulfadiazine	19	19
Isosorbide Mononitrate Er	Isosorbide Mononitrate	18	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	18	suppressed
Levothyroxine Sodium	Levothyroxine Sodium	18	suppressed
Acetic Acid	Acetic Acid	17	17
Fluoxetine Hcl	Fluoxetine Hcl	17	suppressed
Humulin R	Insulin Regular, Human	17	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	17	suppressed
Tradjenta	Linagliptin	17	suppressed
Xarelto	Rivaroxaban	17	suppressed
Alprazolam	Alprazolam	16	suppressed
Etodolac	Etodolac	16	suppressed
Carvedilol	Carvedilol	15	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	15	suppressed
Memantine Hcl	Memantine Hcl	15	suppressed
Methylprednisolone	Methylprednisolone	15	15
Trijardy Xr	Empaglifloz/Linaglip/Metformin	15	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	14	suppressed
Januvia	Sitagliptin Phosphate	14	suppressed
Sure Comfort	Syringe And Needle,insulin,1ml	14	suppressed
Sure Comfort	Syringe-Needle,insulin,0.5 Ml	14	suppressed
Cilostazol	Cilostazol	13	suppressed
Paroxetine Hcl	Paroxetine Hcl	13	suppressed
Synjardy Xr	Empagliflozin/Metformin Hcl	13	suppressed
Atenolol	Atenolol	12	suppressed
Dilantin	Phenytoin Sodium Extended	12	suppressed
Naproxen Sodium	Naproxen Sodium	12	suppressed
Pregabalin	Pregabalin	12	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	12	suppressed
Ultra-Thin Ii	Syringe And Needle,insulin,1ml	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Cefadroxil	Cefadroxil	11	suppressed
Clindamycin Hcl	Clindamycin Hcl	11	suppressed
Risperidone	Risperidone	11	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	11	suppressed
Unifine Pentips Plus	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error